Group 1 - The core viewpoint emphasizes the importance of controlling the progression of myopia in children rather than attempting to reverse it, as most optical methods can only slow down the increase in myopia [2][3] - For children around the age of 10 with myopia under 100 degrees, optical methods like functional frame glasses and OK lenses may show some cases of myopia regression, but this is not common [2] - It is crucial to conduct cycloplegic refraction tests to accurately assess myopia, as traditional vision tests may not detect low degrees of myopia in children who still have normal visual acuity [3] Group 2 - For children who have already developed myopia, intervention measures should be tailored based on the degree of myopia and astigmatism, as well as the individual child's situation [3] - Functional frame glasses or OK lenses are recommended for children with relatively low myopia and high astigmatism, but adjustments should be made based on the child's response and axial growth [3] - Children with low myopia or pure astigmatism may be better suited to wear frame glasses [3]

Core Viewpoint - The company reported strong revenue growth in 2024, but faced a decline in net profit in Q1 2025 due to market pressures from centralized procurement and reduced surgical volumes [1][2]. Financial Performance - In 2024, the company achieved revenue of 1.41 billion yuan, a year-on-year increase of 48.24%, and a net profit of 388 million yuan, up 27.77% [1]. - For Q1 2025, revenue was 357 million yuan, reflecting a year-on-year growth of 15.07%, while net profit decreased to 93 million yuan, down 10.05% [1]. Product Performance - Revenue from artificial crystalline lenses reached 588 million yuan in 2024, growing by 17.66%, with sales volume increasing by 44.93% [2]. - The company’s revenue from myopia control products grew by 20.79%, driven by the introduction of various new products [2]. R&D Investment and New Business Growth - The company increased R&D investment to 160 million yuan in 2024, a rise of 20.80%, representing 11.33% of total revenue [3]. - The contact lens business saw significant growth, with revenue reaching 426 million yuan, a staggering increase of 211.84% [3]. Market Outlook - The company is projected to achieve revenues of 1.81 billion yuan, 2.26 billion yuan, and 2.79 billion yuan for 2025-2027, with respective growth rates of 28.44%, 24.91%, and 23.12% [4]. - Expected net profits for the same period are 467 million yuan, 600 million yuan, and 778 million yuan, with growth rates of 20.21%, 28.55%, and 29.63% [4]. Earnings Per Share - The projected EPS for the years 2025, 2026, and 2027 are 2.46 yuan, 3.17 yuan, and 4.10 yuan respectively [5].